FDA approves first generic of drug used to treat severe hypoglycemia. [ press release ]. Silver Spring, MD: U.S. Food and Drug Administration; December 28, 2020.

Amphastar's generic is a synthetic peptide product that the FDA has deemed to be bioequivalent and thus therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar.

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid.. The FDA ...

Today, the U.S. Food and Drug Administration approved the first generic of glucagon for injection USP, 1 mg/vial packaged in an emergency kit, for the treatment of severe hypoglycemia (very low ...

Amphastar Pharmaceuticals' generic glucagon for injection USP, 1 mg/vial, packaged in an emergency kit, is the first-ever FDA approval of a generic version of rDNA Glucagon.

The Food and Drug Administration last Monday approved the new drug, which comes in a 1-mg vial packaged in an emergency kit. Glucagon is a hormone that spurs the liver to quickly increase blood ...

According to IQVIA, the U.S. sales for Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, 1 mg, were approximately $144 million, and the overall U.S. sales of brand products containing ...

The generic glucagon (Amphastar Pharmaceuticals Inc.) is packaged as a 1 mg vial emergency kit. In its approval, the FDA found the generic glucagon to be bioequivalent and therapeutically ...

(RTTNews) - Amphastar Pharmaceuticals, Inc. (AMPH) said the FDA has approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the ...

About Glucagon Emergency Kit, USP. Glucagon for Injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.

Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes. Fresenius Kabi announced the launch ...

(RTTNews) - The U.S. Food and Drug Administration approved the first generic drug to treat severe hypoglycaemia or dangerously low blood sugar levels, which could occur in patients with diabetes ...